Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: Rational, efficacy, and tolerance

Annals of Hematology

Volumn 91, Issue 10, 2012, Pages 1579-1586

  Horn, Julia ^a   Kleber, Martina ^a   Hieke, Stefanie ^a   Schmitt Gräff, Annette ^a   Wäsch, Ralph ^a   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Aggressive B cell non Hodgkin lymphoma; Bendamustine plus rituximab; Comorbidity; Frail and elderly patients

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BLOOD TOXICITY; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COMORBIDITY; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLICULAR LYMPHOMA; FRAIL ELDERLY; FREIBURG COMORBIDITY INDEX; HEART FAILURE; HEMATOPOIETIC CELL TRASNPLANTATION SPECIFIC COMORBIDITY INDEX; HIGH RISK PATIENT; HUMAN; INFECTION; KAPLAN FEINSTEIN INDEX; KARNOFSKY PERFORMANCE STATUS; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; FRAIL ELDERLY; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NITROGEN MUSTARD COMPOUNDS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84867330981     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1503-5     Document Type: Article

References (35)

1. Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27(9):1492-1501
2. Rummel M, Gregory S (2011) Bendamustine's emerging role in the management of lymphoid malignancies. Semin Hematol 48 (Suppl 1):24-36
3. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Durk H, Rost A, Neise M, von Grunhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23(15):3383-3389
4. Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non- Hodgkin's lymphoma. J Clin Oncol 26(27):4473-4479
5. Pfreundschuh M (2010) How I treat elderly patients with diffuse large B-cell lymphoma. Blood 116(24):5103-5110
6. Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traulle C, Espinouse D, Coiffier B (2008) Non- Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19(4):774-779
7. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235-242
8. van de Schans SA,Wymenga AN, van Spronsen DJ, Schouten HC, Coebergh JW, Janssen-Heijnen ML (2012) Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 23(5):1280-1286
9. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, Rosinol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hajek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118(17):4519-4529
10. Kaplan M, Feinstein A (1974) The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27(7-8):299-305
11. CharlsonM, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245-1251
12. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912-2919
13. Markert A, Thierry V, Kleber M, Behrens M, Engelhardt M (2009) Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment. Int J Cancer 124(3):722-728
14. Engelhardt M, Ihorst G, Udi J, Kleber M, Rawluk J, Wasch R (2011) Does colorectal cancer in ulcerative colitis patients constitute a risk for chemotherapy refractoriness?: a systemic approach by detailed analysis via the electronic tumor base documentation system. Onkologie 34(12):688-694
15. Kleber M, Cybulla M, Bauchmuller K, Ihorst G, Koch B, Engelhardt M (2007) Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol 18(5):950-958
16. Kleber M, Ihorst G, Deschler B, Jakob C, Liebisch P, Koch B, Sezer O, Engelhardt M (2009) Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol 83(6):519-527
17. Kleber M, Ihorst G, Udi J, Koch B,Wasch R, Engelhardt M (2012) Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. Clin Lymphoma Myeloma Leuk 12(1):38-48
18. Kleber M, Ihorst G, Terhorst M, Koch B, Wäsch R, Engelhardt M (2012) Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 1:e35. doi:10.1038/bcj.2011.34
19. Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, Fanin R, Boccadoro M, Corradini P (2009) The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 23(6):1131-1138
20. Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nosslinger T, Makrai A, Stauder R, Krieger O, Pfeilstocker M, Valent P (2010) Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 21(1):114-119
21. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25 (5):579-586
22. Common Terminology Criteria for Adverse Events (CTCAE), 4.02. V (2009) NIH publication no. 03-5410. http://evs.nci.gov/ftp1/CTCAE/About.html
23. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92 (6):1927-1932
24. El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie- Bergman C, Gaillard I, Divine M, Tabah-Fisch I, Reyes F, Haioun C (2007) Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 18 (8):1363-1368
25. Mohren M, Herold M, Scheinpflug K, Wilhelm G, Uhlich J, Schwarzbach H, Franke A (2008) Bendamustin/MabThera in patients with relapsed or refractory aggressive CD 20 cell B-cell lymphoma. Ann Oncol 19(4):5 [Abstract]
26. Kuntz E, Schmitt T, Dietrich S, Bonn S, Ho A, Witzens-Harig M (2010) Rituximab and bendamustine in patients with diffuse large cell CD20+ B-cell lymphoma not eligible for CHOP like chemotherapy. Onkologie 33(6):45 [Abstract]
27. Weßendorf S, Basovski L, Viardot A, Schwaenen C, Kohlhammer H, Sandherr M, Brugger W, Schnalbmann R, Prummer O, van Roye C, Doehner H, Bentz M (2004) Treatment of relapsed aggressive non-Hodgkin-lymphoma in elderly patients using rituximab and bendamustine. Onkologie 27(39):129 [Abstract]
28. Weidmann E, Faith F, Atmaca A, Al-Batran S, Neumann A, Pauligk C, Jäger E (2009) First-line treatment with rituximab and bendamustine in old patients (80 years and older) with aggressive B-cell lymphomas - an interim analysis of ongoing phase II study. Haematologica 94:2 [Abstract]
29. Vacirca J, Tabbara I, Acs P, Shumaker G (2010) Bendamustine + rituximab as treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 116:2806 [Abstract]
30. Weidmann E, Kim S, Rost A, Schuppert H, Seipelt G, Hoelzer D, Mitrou P (2003) Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 13:1285-1289 [Abstract]
31. Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jager E (2011) Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 22(8):1839-1844
32. Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, Andre M, Fournier M, Gaulard P, Tilly H (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, singlearm, phase 2 trial. Lancet Oncol 12(5):460-468
33. Kobayashi Y, Miura K, Hojo A, Hatta Y, Tanaka T, Kurita D, Iriyama N, Kobayashi S, Takeuchi J (2011) Charlson comorbidity index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 137 (7):1079-1084
34. Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M (2010) Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10 (1):21-27
35. Paydas S (2011) Bendamustine and rituximab is effective and costeffective in older cases with aggressive lymphomas? Ann Oncol 22 (12):2694-2695